首页 | 本学科首页   官方微博 | 高级检索  
     


An evaluation of brigatinib as a promising treatment option for non-small cell lung cancer
Authors:G. Hamilton  M.J. Hochmair
Affiliation:1. Department of Surgery, Medical University of Vienna, Vienna, Austriagerhard.hamilton@toc.lbg.ac.at;3. Respiratory Oncology Unit, Otto Wagner Hospital, Vienna, Austria
Abstract:ABSTRACT

Introduction: Brigatinib is a second-line inhibitor for the treatment of rearranged anaplastic lymphoma kinase (ALK) in lung cancer patients which has significant activity against brain metastases. This tyrosine kinase inhibitor (TKI) overcomes a wide range of ALK mutations which confer therapeutic resistance and is increasingly applied in first-line therapy due to improved benefit for patients compared to crizotinib, the current standard of care.

Areas covered: The authors review the development and characteristics of brigatinib and discuss the optimal clinical use and sequence of the application of ALK inhibitors in patients progressing under therapy.

Expert opinion: ALK-rearranged NSCLC can be treated with a broad range of approved and novel inhibitors at various stages of therapy, including the second-line therapeutic brigatinib. Besides this TKI, the second-line ALK inhibitors alectinib and ceritinib, as well as the third-line lorlatinib are approved for the treatment of ALK-positive NSCLC patients. The main challenge is to find sequences and combinations of ALK inhibitors which provide the best benefit for the patients.
Keywords:Lung cancer  anaplastic lymphoma kinase  tyrosine kinase inhibitor  brigatinib
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号